Management of lung cancer patients during COVID-19 pandemic: dos, don'ts and don't knows.
Explor Target Antitumor Ther
; 3(3): 321-336, 2022.
Article
in English
| MEDLINE | ID: covidwho-1965167
ABSTRACT
Aim:
During the coronavirus disease 2019 (COVID-19) pandemic two needs have overlapped on one hand continuing to provide the best care for patients with lung cancer and preventing the spread of the virus between patients and healthcare professionals on the other hand. Due to the pandemic's unpredictable duration, physicians had to evaluate the risk/benefit ratio of anti-cancer therapeutic strategy to do the best for their patients and to protect patients themselves, as well as healthcare workers.Methods:
Systematic literature research was performed with the aim to assess the available guidelines for the management of lung cancer patients during the COVID-19 pandemic. Thirteen potentially relevant articles were selected and recommendations have been divided into three main categories dos, don'ts and don't knows.Results:
All guidelines and recommendations highlighted the relevance of being able to delay, if possible and based on risk stratification, and curative interventions. The selected recommendations should be considered adaptable and flexible because they might be contextualized on the basis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection prevalence and the availability of diagnostic-therapeutic resources.Conclusions:
It remains of fundamental importance to discuss each diagnostic and therapeutic decision with the patient taking into account risks and benefits that might vary from case to case.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Systematic review/Meta Analysis
Language:
English
Journal:
Explor Target Antitumor Ther
Year:
2022
Document Type:
Article
Affiliation country:
Etat.2022.00085
Similar
MEDLINE
...
LILACS
LIS